Close

Hepatitis C (HCV)

Hepatitis C virus (HCV) is an infectious disease that primarily affects the liver. It is the most serious type of hepatitis virus and can lead to cirrhosis and liver failure or cancer. It is estimated that 150–200 million people, or about 3% of the world’s population, are living with chronic HCV.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist
Filter By:
Clear Results
51 Results
Name
Type
Format
Host/Source
Isotype
Tested Apps
Unit
Catalog
SDS
COA
Request Sample
MAb to HCV Core
Monoclonal
Purified
Mouse
IgG1
EIA, Pr
MG
C11423M
HCV NS3/core/NS4/NS5 Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, LF, Pr
MG
R01600
HCV NS3/core/NS4/NS5 Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, LF, Pr
MG
R01599
HCV NS5, Genotype 1a, Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18206
HCV Ns3 C33c Subtype 1a Recomb
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18358
HCV Core Recombinant
Antigen, Other
Purified
Pichia pastoris
N/A
EIA, WB
MG
VTI710
HCV Core/ns3/ns4 Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA
MG
R01548
MAb to HCV Ns-3
Monoclonal
Purified
Mouse
IgG2
EIA, WB
MG
C65859M
MAb Hepatitis C Virus (HCV)
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, Pr
MG
C01252M
MAb to HCV E2
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, WB
MG
C65167M
MAb to HCV NS-3
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, WB
MG
C65371M
MAb to HCV NS-5a
Monoclonal
Purified
Mouse
IgG2a
EIA, IFA, WB
MG
C65388M
MAb to HCV Core antigen
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, IHC, Pr, WB
MG
C65317M
MAb to HCV E1
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, WB
MG
C65198M
MAb to HCV NS-4b
Monoclonal
Purified
Mouse
IgG1
EIA, WB
MG
C01237M
Goat anti HCV Core
Polyclonal
Purified
Goat
N/A
EIA, WB
ML
B65168G
Goat anti HCV NS-3
Polyclonal
Purified
Goat
N/A
EIA, IFA, WB
ML
B65178G
Goat anti HCV NS-4
Polyclonal
Purified
Goat
N/A
EIA, WB
ML
B65188G
HCV Core Ag Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R8A115
HCV NS3 Ag., Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R8A442
MAb to HCV Ns-4b(aa 1710-1730)
Monoclonal
Purified
Mouse
IgG2b
EIA, IHC(f), WB
MG
C8A246M
MAb to HCV Core Ag (a.a.70-90)
Monoclonal
Purified
Mouse
IgG1
EIA, IHC(f), WB
MG
C8A216M
MAb to HCV Ns-4a(aa 1700-1710)
Monoclonal
Purified
Mouse
IgG1
EIA, IHC(f), WB
MG
C8A236M
MAb to HCV Core antigen
Monoclonal
Supernatant
Mouse
IgG1
EIA, WB
MG
C8A116M
MAb to HCV NS-4
Monoclonal
FITC
Mouse
IgG2a
EIA, IFA, IHC(f), WB
MG
C8A018F
MAb to HCV Ns-3 (aa 1350-1460)
Monoclonal
Purified
Mouse
IgG1
EIA, IHC(f)
MG
C8A217M
MAb to HCV Core antigen
Monoclonal
Purified
Mouse
IgG2a
EIA
MG
C8A016M
MAb to HCV Core antigen
Monoclonal
Purified
Mouse
IgG2a
EIA, WB
MG
C8A117M
MAb to HCV NS-4
Monoclonal
Purified
Mouse
IgG2a
EIA, WB
MG
C8A018M
HCV Nucleocapsid/NS3/NS4/NS5
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18523
Goat anti HCV E1
Polyclonal
Purified
Goat
N/A
EIA, IFA, WB
ML
B01437G
HCV NS3,c33c,Subtype 2b,Recomb
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18800
HCV Ns-3 Ag, Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA
MG
R01234
Goat anti HCV E2
Polyclonal
Purified
Goat
N/A
EIA, IFA, WB
ML
B65581G
HCV NS-4a+b Ag Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R8A116
MAb to HCV Core antigen
Monoclonal
FITC
Mouse
IgG2a
EIA, IFA, IHC(f)
MG
C8A016F
MAb to HCV Core antigen
Monoclonal
Purified
Mouse
IgG2a
EIA
MG
C8A017M
MAb Hepatitis C Virus (HCV)
Monoclonal
Purified
Mouse
IgG2a
EIA, Pr
MG
C01251M
HCV Ns4 Ag, Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18541
HCV Core Ag,genotype 1,recomb
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18140
HCV Core Ag,genotype 3,recomb
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18150
HCV NS-4a+b Ag Recomb.
Antigen, Other
FITC
E. coli
N/A
EIA, WB
MG
R8A611
HCV Core Ag, Genotype 5,recomb
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18170
HCV NS5, Genotype 1, Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18190
HCV Core Ag, Genotype 6 Recomb
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18180
HCV Ns3, Genotype 1a, Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA
MG
R01518
MAb Hepatitis C Virus (HCV)
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, Pr, WB
MG
C01253M
MAb to HCV Core antigen
Monoclonal
Biotin
Mouse
IgG2a
EIA
MG
C8A017B
MAb to HCV Core antigen
Monoclonal
Biotin
Mouse
IgG2a
EIA, IHC(f)
MG
C8A016B
MAb to HCV Ns-5a (aa2190-2300)
Monoclonal
Purified
Mouse
IgG1
EIA, IHC(f), WB
MG
C8A256M
MAb to HCV Core
Monoclonal
Purified
Mouse
IgG1
EIA, IFA, WB
MG
C65185M

Hepatitis C (HCV)

There are 6 major strains (genotypes) of HCV worldwide, which vary in their geographic distribution. Genotype 1 is the most common strain worldwide and it is considered to be the most aggressive, followed by genotypes 2 and 3. Genotypes 4, 5 and 6 are more regionally focused to areas such as Africa (type 4), South Africa (type 5) and Southeast Asia and China (type 6). Although HCV genotyping assays are not required to diagnose an HCV infection, it is critical information for prescribing HCV treatment since each strain responds differently to the various medications. Most acute hepatitis infections do not get treated as infected individuals are usually unaware they have been exposed to the virus and they do not develop any symptoms. About 85% of infections will progress to chronic hepatitis and remain undiagnosed for several decades until liver damage is detected during routine medical exams. A chronic HCV infection that is left untreated can cause serious complications including liver cirrhosis, liver cancer and liver failure.

Diagnosis

There are two main types of diagnostic tests for HCV:

  1. serological assays that detect antibody or antigen to HCV
  2. molecular assays that detect, quantify, and/or characterize HCV RNA genomes within an infected patient

Since 1990, serologic-based assays have been used to screen blood donations and to diagnose an HCV infection in symptomatic patients. Molecular assays such as PCR-based tests are generally only used as confirmation or to determine the HCV genotype. Over the years, four generations of anti-HCV tests have been developed, and each generation has resulted in an improvement in the sensitivity of detecting HCV. New-generation tests are now able to detect the total nucleocapsid core antigen whose sequence is highly conserved across all HCV genotypes, allowing for the earlier detection of an HCV infection. These assays employ a cocktail of all genotype recombinant antigens derived from the core, NS3, NS4, and NS5 regions of multiple HCV genotypes and an anti-HCV core antibody with specificity for multiple genotypes.

HCV Core Antigen Test

Hepatitis C core antigen can be detected soon after infection, before the development of antibodies to the virus, and remains detectable throughout chronic infection. Evaluations in transfusion settings have shown that the HCV Core Ag assay detects HCV infection as effectively as NAT, about 40-50 days earlier than the current third generation anti-HCV screening assays. HCV core antigen levels closely follow HCV RNA dynamics, and allow clinical monitoring of a patient’s therapy, independently of HCV genotype.

HCV Antibody Test

The HCV antibody test is commonly used to screen individuals with risk factors, people who have symptoms associated with hepatitis or liver disease, or those who have been exposed to the virus. It is generally followed by a confirmatory nucleic acid test to detect HCV RNA, which indicates an active viral infection. The confirmatory test is essential because between 15 and 50% of people with HCV antibodies will have spontaneously cleared HCV infection during the first six months after exposure and do not have chronic infection. Anti-HCV persists indefinitely in patients who develop chronic infection, although antibodies may become undetectable in hemodialysis patients or in cases of profound immunosuppression.

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

Learn More

Welcome to

Please select your country to continue

Continue
EN